S-3

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

Retrieved on: 
Montag, Januar 29, 2024
CKPT, Prospectus, Form, Regulation D, Sale, Checkpoint, S-3, Telephone, Security (finance)

In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock.

Key Points: 
  • In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock.
  • H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
  • The closing of the offering is expected to occur on or about January 31, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering are expected to be approximately $14 million.

SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

Retrieved on: 
Freitag, Januar 26, 2024
Prospectus, Form, Regulation D, Sale, The Act, S-3, Exercise, Security (finance), Venture round

The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof), accompanying Series A warrants and Series B warrants is $0.8302.

Key Points: 
  • The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof), accompanying Series A warrants and Series B warrants is $0.8302.
  • The Company expects to receive gross proceeds in the amount of approximately $9.0 million from the offering.
  • Maxim Group LLC is acting as the sole placement agent for the offering.
  • The offering is expected to close on or about January 30, 2024, subject to the satisfaction of customary closing conditions.

Akoustis Announces Pricing of Public Offering of $10.0 Million of Common Stock

Retrieved on: 
Donnerstag, Januar 25, 2024
IDM, Research, Prospectus, Public expenditure, Form, Sale, Suite, S-3, Roth Capital Partners, Telephone, BAW, Security (finance), Electronic, Growth

Charlotte, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has priced its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $0.50 per share.

Key Points: 
  • Akoustis expects the gross proceeds from the offering to be approximately $10.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Akoustis.
  • Akoustis has granted the underwriters in the offering a 30-day option to purchase up to 3,000,000 additional shares of common stock solely to cover over-allotments.
  • Akoustis expects to close the offering, subject to market and other conditions, on or about January 29, 2024.
  • 333-262540) relating to the shares of common stock to be issued in the offering was previously filed with the Securities and Exchange Commission (the “SEC”) and is currently effective.

Castellum Announces Pricing of $2.7 Million Registered Direct Offering

Retrieved on: 
Donnerstag, Januar 25, 2024
Prospectus, Form, Regulation D, Sale, Federation, CTM, S-3, Telephone, Attention, Exercise, Act, Security (finance)

The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $0.32.

Key Points: 
  • The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $0.32.
  • The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $2.7 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company.
  • The offering is expected to close on or about January 29, 2024, subject to the satisfaction of customary closing conditions.
  • Maxim Group LLC is acting as the sole placement agent in connection with the offering.

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Donnerstag, Januar 25, 2024
Jefferies, Patient, Madison Avenue, Guggenheim Partners, Jefferies Group, TRML, Nicollet Mall, Floor, Prospectus, Form, Sale, Tourmaline, S-3, Inflammation, Truist, Attention, Telephone, Security (finance)

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share.

Key Points: 
  • NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share.
  • The gross proceeds to Tourmaline from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $150.0 million.
  • All of the common stock is being offered by Tourmaline.
  • In addition, Tourmaline has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of common stock at the public offering price, less the underwriting discounts and commissions.

Tourmaline Bio Announces Proposed Public Offering of Common Stock

Retrieved on: 
Mittwoch, Januar 24, 2024
Jefferies, Patient, Madison Avenue, Guggenheim Partners, Jefferies Group, TRML, Nicollet Mall, Floor, Prospectus, Form, Sale, Tourmaline, S-3, Inflammation, Truist, Attention, Telephone, Security (finance)

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock.

Key Points: 
  • NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock.
  • All shares of common stock to be sold in the proposed offering will be sold by Tourmaline.
  • In addition, Tourmaline expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the number of shares of common stock sold in the offering.
  • The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Alector Announces Closing of Public Offering

Retrieved on: 
Freitag, Januar 19, 2024
Capital market, Alector, SAN, Prospectus, ALEC, Form, Sale, S-3, Attention, Security (finance)

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock.
  • Alector sold 10,869,566 shares of its common stock in the offering.
  • Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock.
  • The gross proceeds to Alector from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $75 million.

SurgePays Announces Proposed Public Offering

Retrieved on: 
Mittwoch, Januar 17, 2024
Titan, SURG, Prospectus, Form, Sale, S-3, Security (finance)

BARTLETT, Tenn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- SurgePays, Inc. (Nasdaq: SURG) (“SurgePays”), a technology and telecom company focused on the underbanked and underserved communities, today announced that it has commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • BARTLETT, Tenn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- SurgePays, Inc. (Nasdaq: SURG) (“SurgePays”), a technology and telecom company focused on the underbanked and underserved communities, today announced that it has commenced an underwritten public offering of shares of its common stock.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
  • All of the shares of common stock to be sold in the proposed offering will be sold by SurgePays.
  • Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the proposed offering.

Alector Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Mittwoch, Januar 17, 2024
Capital market, Alector, SAN, Prospectus, ALEC, Form, Sale, S-3, Attention, Security (finance)

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector.
  • The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions.
  • All of the shares in the offering are being sold by Alector.
  • Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions.

Sidus Space Announces Proposed Public Offering

Retrieved on: 
Montag, Januar 29, 2024
Other Manufacturing, Technology, Finance, Engineering, Satellite, Professional Services, Aerospace, Manufacturing, Hardware, Data Management, ThinkEquity, Sale, Form, Sidus, State Street, S-3, Prospectus, Warrant

Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced that it intends to offer to sell shares of its Class A common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering.

Key Points: 
  • Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), a multi-faceted Space and Data-as-a-Service company, today announced that it intends to offer to sell shares of its Class A common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering.
  • ThinkEquity is acting as sole book-running manager for the offering.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.